• Fri, November 11, 2022

Geulah Livshits Maintained (CABA) at Strong Buy with Decreased Target to $12 on, Nov 11th, 2022

Geulah Livshits of Chardan Capital, Maintained "Cabaletta Bio, Inc." (CABA) at Strong Buy with Decreased Target from $13 to $12 on, Nov 11th, 2022.

Geulah has made no other calls on CABA in the last 4 months.



There are 2 other peers that have a rating on CABA. Out of the 2 peers that are also analyzing CABA, 1 agrees with Geulah's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $3 on, Tuesday, August 30th, 2022


This is the rating of the analyst that currently disagrees with Geulah


  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $4 on, Wednesday, September 14th, 2022

Like: 👍